Showing results (141-150 of 207) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Improvement of overall survival in advanced stage mantle cell lymphomaAnnina Herrmann, Eva Hoster, Thomas Zwingers, et al.
Ejhaem|February 23, 2023
Ars2-containing bispecific, Fab- and IgG1-format BAR-bodies to target DLBCL cellsMaximilian Kiefer, Lorenz Thurner, Theresa Bock, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2011
High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation RegistryNicolas Mounier, Carmen Canals, Christian Gisselbrecht, et al.
Hemasphere|July 15, 2021
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma CellsMoritz Bewarder, Maximilian Kiefer, Helene Will, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study groupMichael Pfreundschuh, Viola Poeschel, Samira Zeynalova, et al.
Genes, Chromosomes & Cancer|October 18, 2012
High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomasItziar Salaverria, Idoia Martin-Guerrero, Birgit Burkhardt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2021
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Gerhard Held, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2009
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 studyAndreas Engert, Volker Diehl, Jeremy Franklin, et al.
Pageof 21